MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-101497-PIP01-24

Scope of the Application

Active Substance(s)

laruparetigene zovaparvovec; Recombinant Adeno-Associated Viral Vector Expressing a Human RPGR1-14,ORF15gene (rAAV2tYF-GRK1-RPGR)

Condition(s)

Treatment of X-linked retinitis pigmentosa (XLRP)

Pharmaceutical Form(s)

Solution for injection

Route(s) of Administration

INTRAOCULAR USE

Name / Corporate name of the PIP applicant

Beacon Therapeutics

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Beacon Therapeutics submitted to the licensing authority on 28/06/2024 23:19 BST an application for a Paediatric Investigation Plan

The procedure started on 03/09/2024 08:28 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101497-PIP01-24

Of 08/10/2024 18:29 BST

On the adopted decision for laruparetigene zovaparvovec; Recombinant Adeno-Associated Viral Vector Expressing a Human RPGR1-14,ORF15gene (rAAV2tYF-GRK1-RPGR) (MHRA-101497-PIP01-24) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for laruparetigene zovaparvovec; Recombinant Adeno-Associated Viral Vector Expressing a Human RPGR1-14,ORF15gene (rAAV2tYF-GRK1-RPGR) , Solution for injection , INTRAOCULAR USE .

This decision is addressed to Beacon Therapeutics, 188 York Way, Rolling Stock Yard, 2nd floor, London, UNITED KINGDOM, N7 9AS

ANNEX I

1. Waiver

1.1 Condition:

Treatment of X-linked retinitis pigmentosa (XLRP) The waiver applies / applied to: Paediatric Subset(s): Females from birth to less than 18 years of age Males from birth to less than 5 years of age Pharmaceutical form(s): Solution for injection Route(s) of administration: INTRAOCULAR USE Reason for granting waiver: For females from birth to less than 18 years of age • on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s). For males from birth to less than 5 years of age • on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of X-linked retinitis pigmentosa (XLRP)

2.2 Indication(s) targeted by the PIP:

Treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Males from 5 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	5	Study 1 (Horizon dose escalation study) Non-randomised, open-label, dose escalation study to evaluate the safety and efficacy of laruparetigene zovaparvovec in male children and adolescents from 6 years to less than 18 years of age (and adults) with X-linked retinitis pigmentosa (XLRP). Study 2 (Skyline study) Randomised, controlled, masked, multi-centre study comparing the efficacy, safety, and tolerability of two doses of laruparetigene zovaparvovec in male children and adolescents from 8 years to less than 18 years of age (and adults) with XLRP. Study 3 (Dawn study) Open-label fellow eye dosing study of the safety of laruparetigene zovaparvovec in male adolescents from 12 years to less than 18 years of age (and adults) with XLRP administered in the fellow eye of participants treated with laruparetigene zovaparvovec in either the Horizon or Skyline study (PIP

		studies 1 and 2). Study 4 (Pivotal Vista study [AGTC-RPGR-002]) Randomised, controlled, masked, multi-centre study to evaluate the efficacy, safety, and tolerability of two doses of laruparetigene zovaparvovec compared to an untreated control group in male adolescents aged 12 years to less than 18 years (and adults) with XLRP. Study 5 (AGTC-RPGR-003) Open-label, multi-centre study in children from 5 years to less than 12 years of age to assess the safety of laruparetigene zovaparvovec to treat XLRP.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	30/06/2034
Deferral of one or more studies contained in the paediatric investigation plan:	Yes